InstitutionClaim Cited
Novo Nordisk
Novo Nordisk combines a publicly traded pharmaceutical company with foundation-backed voting control, joining long-horizon ownership and scientific philanthropy to a commercial medicine business whose legitimacy still depends on whether patients can reach what it invents.
What does foundation control change when a life-sciences company must simultaneously preserve research capacity, compete for capital, and serve patients who cannot treat medicine as an optional product?